#USA #New York #NYU Langone #Prostate Cancer #cryotherapy

NYU Langone Celebrates 1,000 Cryotherapy Procedures for Prostate Cancer

In a noteworthy development in the treatment of prostate cancer, NYU Langone Health has proudly marked its 1,000th outpatient focal cryotherapy procedure. This innovative treatment has been revolutionizing how prostate cancer is managed, significantly benefiting patients with localized forms of the disease, allowing them to return to their daily lives rapidly.

One of the most remarkable examples is Broadway star André De Shields, who, at the age of 80, was able to return to the stage just two days after undergoing treatment. His story reflects a broader trend in modern cancer care, which emphasizes not only surviving the disease but thriving afterward. De Shields received focal cryotherapy, which is known for its minimally invasive nature and effectiveness in preserving quality of life post-treatment.

A Milestone in Cancer Treatment

Focal cryotherapy, often referred to as focal cryoablation, involves using controlled freezing to target and destroy cancer cells within the prostate while sparing surrounding healthy tissues. This procedure is particularly suited for patients like De Shields, whose cancer is confined to specific areas of the prostate. Traditional treatments such as radical surgery and radiation often come with serious side effects, including long-term urinary and sexual dysfunction, which focal cryotherapy aims to avoid.

NYU Langone staff, including Dr. Herbert Lepor, the director of the Smilow Comprehensive Prostate Cancer Center, have been leading the charge in this innovative treatment since they first performed the procedure in 2017. The success of these procedures has contributed to their growing popularity, as patients appreciate the opportunity to maintain their quality of life and minimize treatment-related complications.

Focus on Patient-Centric Care

Bill Megela's experience further highlights the effectiveness and patient-centric approach of NYU Langone's services. Diagnosed with prostate cancer in 2018, Megela was presented with traditional treatment options that posed significant risks of adverse effects. Instead, he opted for focal cryotherapy upon learning about its benefits. Now, years later, he remains cancer-free and enjoys a fulfilling life without the major side effects that might have followed more invasive procedures.

Megela's sentiment is echoed by many patients who are realizing that advancements in cancer therapies cater to their overall well-being. As Dr. Lepor emphasizes, the goal is not just to treat cancer but also to ensure that patients lead active, healthy lives after treatment.

Reassuring Results and Future Prospects

The success of focal cryotherapy extends beyond mere anecdotal outcomes; studies have shown that preserved urinary and sexual functions following treatment are substantial motivators for both physicians and patients. The team's commitment to conducting clinical research and continuously evaluating patient outcomes has not only driven innovation but also established NYU Langone as a leader in the field.

The structured, multidisciplinary approach ensures that patients receive comprehensive care tailored to their individual needs, thereby enabling them to focus on recovery and future aspirations. Physicians like Dr. Lepor take pride in supporting patients as they navigate through their cancer journey, prioritizing effective and compassionate care.

The Broader Landscape of Cancer Care

As NYU Langone expands its focus on innovative treatments like focal cryotherapy, the health landscape continues to evolve, emphasizing personal stories and successes. The implementation of such breakthrough procedures highlights a shift towards patient empowerment in their treatment choices, fostering a culture where patients can thrive beyond their diagnoses.

With more than 1,000 successful procedures under its belt, NYU Langone Health continues to set benchmarks in the field of urologic oncology, influencing the broader horizon of cancer care.

In conclusion, the journey of NYU Langone's cryotherapy initiative signifies a profound impact not only on individual lives but also on the medical community's approach to prostate cancer treatment. Patients like André De Shields and Bill Megela inspire a positive dialogue about survivorship and the potential for rapid recovery following a cancer diagnosis.